## Levodopa vs Dopamine Agonists: Key Discriminator ### Motor Complications Profile **Key Point:** Motor fluctuations (wearing-off, on-off phenomena) and dyskinesias are hallmark complications of levodopa therapy but are significantly less common with dopamine agonists as monotherapy. ### Mechanism of Difference Levodopa causes pulsatile dopaminergic stimulation due to its short half-life (~60–90 minutes) and dependence on enzymatic conversion. This pulsatile pattern leads to: - Wearing-off effects (symptom return before next dose) - Peak-dose dyskinesias (involuntary movements at peak drug levels) - Diphasic dyskinesias (dyskinesias at dose onset and offset) Dopamine agonists (bromocriptine, ropinirole, pramipexole) provide more continuous receptor stimulation with longer half-lives, resulting in smoother dopaminergic tone and fewer motor complications when used as monotherapy. ### Comparative Table | Feature | Levodopa | Dopamine Agonists | |---------|----------|-------------------| | Motor fluctuations | Common (>50% at 5 years) | Rare as monotherapy | | Dyskinesias | Frequent | Uncommon | | Half-life | 60–90 min | 3–12 hours | | Stimulation pattern | Pulsatile | Continuous | | Age at onset risk | Increases with younger age | Lower risk | **High-Yield:** This distinction is critical for treatment selection—younger patients are often started on dopamine agonists to delay levodopa-induced motor complications. **Clinical Pearl:** While levodopa remains the most potent antiparkinsonian agent, the emergence of motor complications after 5–10 years of therapy is a major limitation that guides initial drug choice. [cite:KD Tripathi 8e Ch 12]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.